Flex Pharma, Inc. (NASDAQ: FLKS) announced that it has initiated a Phase 2 efficacy study in amyotrophic lateral sclerosis (ALS) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE